Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

611.38 +14.85 (+2.49%)
Streaming Delayed Price Updated: 3:47 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 780,614
Open 595.01
Bid (Size) 610.93 (1)
Ask (Size) 611.84 (2)
Prev. Close 596.54
Today's Range 595.01 - 615.20
52wk Range 520.50 - 1,211.20
Shares Outstanding 91,779,465
Dividend Yield 0.14%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's going on in today's session: S&P500 movers
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal
Regeneron (REGN) to acquire 23andMe for $256 million, plans to maintain consumer services and uphold privacy policies. Deal expected to close Q3 2025. 
Via Benzinga

Performance

YTD
-14.5%
-14.5%
1 Month
+8.9%
+8.9%
3 Month
-10.1%
-10.1%
6 Month
-19.8%
-19.8%
1 Year
-38.1%
-38.1%

More News

Read More
Regeneron To Buy Assets Of 23andMe For $256M: Retail Says ‘Fantastic’ For Future R&D Efforts
Via Stocktwits
Topics Artificial Intelligence Bankruptcy
Exposures Artificial Intelligence Financial Legal
23andMe Finds A Big Biotech Buyer In $256 Million Bankruptcy Auction
Via Investor's Business Daily
Topics Bankruptcy
Exposures Financial Legal
Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale
From 23andMe, Inc.
Via GlobeNewswire
3 Stocks That Will Profit From Trump's Drug Price Cut
Via Benzinga
Topics Government
Exposures Political
75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
1 Nasdaq 100 Stock with Exciting Potential and 2 to Think Twice About
Via StockStory
Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025
Via MarketBeat
Topics Government World Trade
Exposures Political Tariff
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Via Benzinga
Beyond The Numbers: 16 Analysts Discuss Regeneron Pharmaceuticals Stock
Via Benzinga
Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards?
Via Benzinga
Topics Stocks
Exposures US Equities
This PVH Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
Best Biotech Stocks to Buy in 2025
Via MarketBeat
Topics ETFs Economy Government
Exposures COVID-19 Interest Rates Political
REGN Q1 Earnings Call: Pipeline Progress and EYLEA Headwinds Dominate Discussion
Via StockStory
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket
Via Benzinga
Topics Government
Exposures Political
3 of Wall Street’s Favorite Stocks Skating on Thin Ice
Via StockStory
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?
Via Benzinga
1 Cash-Heavy Stock on Our Buy List and 2 to Ignore
Via StockStory
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.
Via Chartmill
Discover which S&P500 stocks are making waves on Thursday.
Via Chartmill
Thursday's session: gap up and gap down stock in the S&P500 index
Via Chartmill

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 611.38
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 05/20/25 03:47 PM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 56.11B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 56B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.